120 related articles for article (PubMed ID: 31602489)
1. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Sakellariou-Thompson D; Forget MA; Hinchcliff E; Celestino J; Hwu P; Jazaeri AA; Haymaker C; Bernatchez C
Cancer Immunol Immunother; 2019 Nov; 68(11):1747-1757. PubMed ID: 31602489
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB Agonist Focuses CD8
Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C
Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567
[No Abstract] [Full Text] [Related]
3. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1
Salas-Benito D; Conde E; Tamayo-Uria I; Mancheño U; Elizalde E; Garcia-Ros D; Aramendia JM; Muruzabal JC; Alcaide J; Guillen-Grima F; Minguez JA; Amores-Tirado J; Gonzalez-Martin A; Sarobe P; Lasarte JJ; Ponz-Sarvise M; De Andrea CE; Hervas-Stubbs S
Br J Cancer; 2021 Mar; 124(6):1138-1149. PubMed ID: 33402737
[TBL] [Abstract][Full Text] [Related]
4. In vitro 4-1BB stimulation promotes expansion of CD8
Nielsen M; Krarup-Hansen A; Hovgaard D; Petersen MM; Loya AC; Westergaard MCW; Svane IM; Junker N
Cancer Immunol Immunother; 2020 Nov; 69(11):2179-2191. PubMed ID: 32472369
[TBL] [Abstract][Full Text] [Related]
5. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours.
Schöndorf T; Engel H; Lindemann C; Kolhagen H; von Rücker AA; Mallmann P
Cancer Immunol Immunother; 1997 Apr; 44(2):88-96. PubMed ID: 9177470
[TBL] [Abstract][Full Text] [Related]
6. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
[TBL] [Abstract][Full Text] [Related]
7. Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection.
Balzeau J; Ravindran A; Wang X; Maisuria J; Lucchesi A; Yao H; Matsueda S
Cancer Immunol Immunother; 2023 Oct; 72(10):3377-3385. PubMed ID: 37468658
[TBL] [Abstract][Full Text] [Related]
8. Characterization of tumor-necrosis-factor-gene-transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production.
Itoh Y; Koshita Y; Takahashi M; Watanabe N; Kohgo Y; Niitsu Y
Cancer Immunol Immunother; 1995 Feb; 40(2):95-102. PubMed ID: 7882388
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-1derived iPS cells.
Ito T; Kawai Y; Yasui Y; Iriguchi S; Minagawa A; Ishii T; Miyoshi H; Taketo MM; Kawada K; Obama K; Sakai Y; Kaneko S
Commun Biol; 2021 Jun; 4(1):694. PubMed ID: 34099861
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.
Wang S; Sun J; Chen K; Ma P; Lei Q; Xing S; Cao Z; Sun S; Yu Z; Liu Y; Li N
BMC Med; 2021 Jun; 19(1):140. PubMed ID: 34112147
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Jiménez-Sánchez A; Memon D; Pourpe S; Veeraraghavan H; Li Y; Vargas HA; Gill MB; Park KJ; Zivanovic O; Konner J; Ricca J; Zamarin D; Walther T; Aghajanian C; Wolchok JD; Sala E; Merghoub T; Snyder A; Miller ML
Cell; 2017 Aug; 170(5):927-938.e20. PubMed ID: 28841418
[TBL] [Abstract][Full Text] [Related]
12. Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
Quixabeira DCA; Jirovec E; Pakola S; Havunen R; Basnet S; Santos JM; Kudling TV; Clubb JHA; Haybout L; Arias V; Grönberg-Vähä-Koskela S; Cervera-Carrascon V; Pasanen A; Anttila M; Tapper J; Kanerva A; Hemminki A
Cancer Gene Ther; 2023 Nov; 30(11):1543-1553. PubMed ID: 37666898
[TBL] [Abstract][Full Text] [Related]
13. World's first TIL therapy approved.
Nat Biotechnol; 2024 Mar; 42(3):349. PubMed ID: 38491286
[No Abstract] [Full Text] [Related]
14. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616554
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
[TBL] [Abstract][Full Text] [Related]
16. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
Mitra A; Andrews MC; Roh W; De Macedo MP; Hudgens CW; Carapeto F; Singh S; Reuben A; Wang F; Mao X; Song X; Wani K; Tippen S; Ng KS; Schalck A; Sakellariou-Thompson DA; Chen E; Reddy SM; Spencer CN; Wiesnoski D; Little LD; Gumbs C; Cooper ZA; Burton EM; Hwu P; Davies MA; Zhang J; Bernatchez C; Navin N; Sharma P; Allison JP; Wargo JA; Yee C; Tetzlaff MT; Hwu WJ; Lazar AJ; Futreal PA
Nat Commun; 2020 Apr; 11(1):1839. PubMed ID: 32296058
[TBL] [Abstract][Full Text] [Related]
17. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M; Khong H; Fa'ak F; Bentebibel SE; Janssen LME; Chesson BC; Creasy CA; Forget MA; Kahn LMS; Pazdrak B; Karki B; Hailemichael Y; Singh M; Vianden C; Vennam S; Bharadwaj U; Tweardy DJ; Haymaker C; Bernatchez C; Huang S; Rajapakshe K; Coarfa C; Hurwitz ME; Sznol M; Hwu P; Hoch U; Addepalli M; Charych DH; Zalevsky J; Diab A; Overwijk WW
Nat Commun; 2020 Jan; 11(1):661. PubMed ID: 32005826
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive T cell repertoire characterization of non-small cell lung cancer.
Reuben A; Zhang J; Chiou SH; Gittelman RM; Li J; Lee WC; Fujimoto J; Behrens C; Liu X; Wang F; Quek K; Wang C; Kheradmand F; Chen R; Chow CW; Lin H; Bernatchez C; Jalali A; Hu X; Wu CJ; Eterovic AK; Parra ER; Yusko E; Emerson R; Benzeno S; Vignali M; Wu X; Ye Y; Little LD; Gumbs C; Mao X; Song X; Tippen S; Thornton RL; Cascone T; Snyder A; Wargo JA; Herbst R; Swisher S; Kadara H; Moran C; Kalhor N; Zhang J; Scheet P; Vaporciyan AA; Sepesi B; Gibbons DL; Robins H; Hwu P; Heymach JV; Sharma P; Allison JP; Baladandayuthapani V; Lee JJ; Davis MM; Wistuba II; Futreal PA; Zhang J
Nat Commun; 2020 Jan; 11(1):603. PubMed ID: 32001676
[TBL] [Abstract][Full Text] [Related]
19. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.
Wang X; Yuan Z; Li Z; He X; Zhang Y; Wang X; Su J; Wu X; Li M; Du F; Chen Y; Deng S; Zhao Y; Shen J; Yi T; Xiao Z
Front Immunol; 2024; 15():1354313. PubMed ID: 38426090
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
